|6.64||-0.0500||-0.75%||Vol 2.73M||1Y Perf 13.39%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||11.60||Analyst Rating||Strong Buy 1.00|
|Potential %||74.70||Finscreener Ranking||★★★★★ 60.09|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★★ 62.72|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★★ 83.92|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||47.72||Earnings Rating||Buy|
|Market Cap||682.46M||Earnings Date||8th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|10 Years||1 092.10%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Aug 2022|
|Estimated EPS Next Report||0.17|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.19M|
|Avg. Monthly Volume||1.01M|
|Avg. Quarterly Volume||1.10M|
Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 6.64 per share at the end of the most recent trading day (a -0.75% change compared to the prior day closing price) with a volume of 2.73M shares and market capitalization of 682.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.
The one-year performance of Catalyst Pharmaceuticals Inc. stock is 13.39%, while year-to-date (YTD) performance is -1.92%. CPRX stock has a five-year performance of 133.8%. Its 52-week range is between 4.81 and 8.645, which gives CPRX stock a 52-week price range ratio of 47.72%
Catalyst Pharmaceuticals Inc. currently has a PE ratio of 15.90, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 4.17, a price to cashflow ratio of 11.10, a PEG ratio of 2.32, a ROA of 20.80%, a ROC of 22.13% and a ROE of 23.17%. The company’s profit margin is 29.29%, its EBITDA margin is 39.10%, and its revenue ttm is $153.72 Million , which makes it $1.50 revenue per share.
Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.17 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is 08th Aug 2022.
The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1), with a target price of $11.6, which is +74.70% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Catalyst Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.70, ATR14 : 0.34, CCI20 : -39.86, Chaikin Money Flow : 0.07, MACD : -0.18, Money Flow Index : 32.90, ROC : -7.39, RSI : 45.33, STOCH (14,3) : 38.89, STOCH RSI : 0.86, UO : 51.77, Williams %R : -61.11), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $530 400), Alicia Grande (Sold 113 000 shares of value $640 779 ), Brian Elsbernd (Option Excercise at a value of $0), Charles B. O'Keeffe (Option Excercise at a value of $156 000), David S. Tierney (Option Excercise at a value of $206 600), David S. Tierney (Sold 70 000 shares of value $303 895 ), Donald A. Denkhaus (Option Excercise at a value of $268 700), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 7 224 shares of value $50 474 ), Patrick J. McEnany (Option Excercise at a value of $936 000), Patrick J. McEnany (Sold 199 493 shares of value $1 147 646 ), Philip H. Coelho (Option Excercise at a value of $156 000), Philip H. Coelho (Sold 28 540 shares of value $157 780 ), Richard J. Daly (Option Excercise at a value of $167 500), Steven R. Miller (Option Excercise at a value of $577 200), Steven R. Miller (Sold 120 963 shares of value $694 056 )
Thu, 12 May 2022 10:25 GMT Analysts Are Bullish on Top Healthcare Stocks: Catalyst Pharma (CPRX), Veru (VERU)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.